NCT07188376 Mitigating the Disinhibiting Effects of Alcohol With Transcranial Magnetic Stimulation
| NCT ID | NCT07188376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Michael J. Wesley, PhD |
| Condition | Alcohol Risk Behaviors |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2025-10-30 |
| Primary Completion | 2026-08-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12 participants in total. It began in 2025-10-30 with a primary completion date of 2026-08-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn how a specific type of brain stimulation affects alcohol-related decision-making and self-control in adults who drink alcohol. The main questions the study aims to answer are: * Does brain stimulation change how people behave after drinking alcohol? * Does the combination of alcohol and different types of brain stimulation affect people's ability to make thoughtful decisions or resist impulses? Researchers will compare the effects of two types of brain stimulation, intermittent theta burst stimulation (iTBS) and continuous theta burst stimulation (cTBS), after people drink alcohol or a placebo drink. A sham (placebo) stimulation condition will also be included. The study uses a within-person design, which means each participant will take part in all conditions. Participants will: * Attend five separate study visits * Drink either an alcoholic or placebo beverage * Receive one of the brain stimulation conditions (real or sham) * Complete decision-making tasks before and after drinking The tasks will measure things like impulsive choices and reaction time. The researchers hope this study will help identify how brain stimulation could be used to improve decision-making during intoxication, which might one day reduce harmful drinking behaviors or prevent alcohol-related accidents.
Eligibility Criteria
Inclusion Criteria: * Age 21-29 * Must be competent in English * BMI between 19 and 26 * At least a high school education * Moderate alcohol users (e.g., at least occasional alcohol use, without meeting criteria for alcohol use disorder) * Negative urine drug screen for illicit drugs * Negative urine pregnancy test (if applicable) on testing days Exclusion Criteria: * History of seizures or a first-degree relative with seizure history * History of head trauma or other CNS injuries * Current or past psychiatric disorders (including substance use disorder, except nicotine or caffeine) * Contraindications for non-invasive brain stimulation (e.g., metal implants, pacemaker) * Currently pregnant or breastfeeding * Current use of medications that lower seizure threshold * Positive alcohol withdrawal symptoms * Smokes more than five cigarettes per day (to avoid acute nicotine effects or withdrawal during visits)
Contact & Investigator
Michael Wesley, PhD
PRINCIPAL INVESTIGATOR
University of Kentucky
Frequently Asked Questions
Who can join the NCT07188376 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 29 Years, studying Alcohol Risk Behaviors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07188376 currently recruiting?
Yes, NCT07188376 is actively recruiting participants. Contact the research team at michael.wesley@uky.edu for enrollment information.
Where is the NCT07188376 trial being conducted?
This trial is being conducted at Lexington, United States.
Who is sponsoring the NCT07188376 clinical trial?
NCT07188376 is sponsored by Michael J. Wesley, PhD. The principal investigator is Michael Wesley, PhD at University of Kentucky. The trial plans to enroll 12 participants.